Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470…
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates…
Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial
The investigational AeroNova® System delivers continual diaphragm neurostimulation in conjunction with mechanical…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
March 03, 2025 09:27 ET | Source: Pliant Therapeutics, Inc. SOUTH SAN…
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
HARRISON, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Serenity Medical, a NeuroTechnology…
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique…
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025 17:30 ET | Source: AnaptysBio, Inc. SAN DIEGO, Feb.…
GCCL Applauded by Frost & Sullivan for Ensuring Consistent, Reliable Clinical Trial Data in APAC
GCCL is committed to customer success, emphasizing quality control at every stage—from…
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS),…